Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
GENEVA, Feb. 3 /PRNewswire/ --
-- The Six-Month Primary Efficacy Endpoint of the Study was met: Both
Doses of Investigational Agent
Safinamide Significantly Increased "ON" Time in
Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease
-- Secondary Efficacy Endpoi...
Phase III Data on Safinamide in Parkinson’s Disease Presented
at American Academy of Neurology 59th Annual Meeting
GENEVA, Switzerland, May 2, 2007 – Merck
Serono S.A. (virt-x: SEO) announced today that Phase III data on
safinamide, a new agent in Phase III development for the treatment
of Parkinson’s disease symptoms, were presented by Professor
Fabrizio Stocchi at the American Academy of Neur...
Promising Data on Cognitive Effects of Safinamide in Early
Parkinson's Disease
• Data presented at Movement Disorder Society’s 11th
International Congress
• Management of cognitive impairment in early
Parkinson’s disease patients is a critical unmet medical
need
Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.
(virt-x: SEO) and its partne...
Merck Serono Announces Presentation of Phase III Clinical Data on
Safinamide in Parkinson’s Disease at the American Academy of
Neurology 59th Annual Meeting
...resent the results of the first
Phase III trial of
safinamide as an adjunctive treatment to
dopamine agonists (D...e rights to
develop, manufacture and commercialise
safinamide in
Merck Serono 9 Chemin des Mines Corporate .... Recent
results of a six-month phase III trial of
safinamide in PD
demonstrated its benefit in motor symptoms a...